Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSK42360-Na in BRAF V600 Mutated Solid Tumors
NCT07561554Phase 1Recruiting
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Mar 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of HSK42360-Na in solid tumor (2 arms), sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoints: Maximum Tolerated Dose at 52 months, Dose-Limiting Toxicities at 52 months and 4 more. Started Mar 2026; status: recruiting.
02
Drugs
HSK42360-Na
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07561554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07561554.